Experimental drug for rare bone marrow disease shows early promise, but study halted

NCT ID NCT04409080

Terminated Disease control Sponsor: Regeneron Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested an experimental drug called REGN7257 in 17 people with severe aplastic anemia, a rare condition where the bone marrow stops making enough blood cells. The drug was given to patients whose disease did not get better or came back after standard immune-suppressing treatments. The main goal was to check safety and see if the drug could improve blood cell counts, but the study was stopped early.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SEVERE APLASTIC ANEMIA (SAA) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acquired aplastic anemia aplastic anemia Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SEVERE APLASTIC ANEMIA (SAA)

Contacts and locations

Locations

Cleveland Clinic Foundation

Cleveland, Ohio, 44195, United States
Ewha Womans University Medical Centre

Seoul, Seoul Capital Area, 07985, South Korea
Gachon University Gil Hospital

Incheon, Gyeonggi-do, 21565, South Korea
Hopital Saint-Louis - APHP

Paris, Île-de-France Region, 75010, France
King's College Hospital, London

London, SE5 9RS, United Kingdom
Samsung Medical Center

Seoul, Seoul Capital Area, 06351, South Korea
Seoul National University Hospital

Seoul, Seoul Capital Area, 03080, South Korea
St James's University Hospital

Leeds, West Yorkshire, LS97TF, United Kingdom
The Catholic University of Korea, Seoul St. Marys Hospital

Seoul, Seoul Capital Area, 06591, South Korea
The University of Texas MD Anderson Cancer Center

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.